TTHX1114(NM141) in Combination With DWEK/DSO

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Open label, single-treatment, with a concurrent non-treatment control

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Trefoil Therapeutics, Inc.

Criteria

Key Inclusion Criteria:

• Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months

• Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm

• Subjects in Group 2 must have a stable Fellow Eye with adequate function

Key Exclusion Criteria:

• Secondary corneal/ocular pathology in the Study Eye

• Prior refractive surgery in the Study Eye

• Prior exposure to TTHX1114